ANO1 and cystic fibrosis: For instance, TMEM16A channels have been proposed as possible therapeutic targets for respiratory diseases of impaired mucus clearance, including cystic fibrosis, chronic obstructive pulmonary disease and asthma (Huang et al.,2012b; Sondo et al.,2014; Sala‐Rabanal et al.,2015).